您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (7): 22-27.doi: 10.6040/j.issn.1671-7554.0.2014.175

• 基础医学 • 上一篇    下一篇

胰岛素对前列腺癌LNCaP细胞的抑制作用

王琛, 唐悦清, 闫磊, 焦伟, 周尊林, 徐忠华   

  1. 山东大学齐鲁医院泌尿外科, 山东 济南 250012
  • 收稿日期:2014-03-28 修回日期:2014-05-27 出版日期:2014-07-10 发布日期:2014-07-10
  • 通讯作者: 徐忠华。E-mail：xuzhonghua1963@163.com；周尊林。E-mail：zhouzunlin117@163.com E-mail:xuzhonghua1963@163.com;zhouzunlin117@163.com
  • 基金资助:
    山东省科学技术发展项目（26010104011178）

Inhibitory effect of insulin on prostate cancer LNCaP cell line

WANG Chen, TANG Yueqing, YAN Lei, JIAO Wei, ZHOU Zunlin, XU Zhonghua   

  1. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2014-03-28 Revised:2014-05-27 Online:2014-07-10 Published:2014-07-10

PDF (PC)

528

摘要： 目的 观察胰岛素对前列腺癌LNCaP细胞系增殖、活力、迁移与侵袭能力的影响，并探讨其机制。方法 胰岛素刺激LNCaP细胞后，采用实时荧光定量聚合酶链反应（Real-time PCR）、蛋白免疫印迹（Western blotting）、免疫细胞化学（ICC）法检测胰岛素受体表达变化；细胞计数法、四唑盐法（MTT）、细胞划痕、细胞侵袭实验（Transwell）检测细胞增殖、活力、迁移和侵袭能力；Western blotting检测Ras、ERK1/2、MEK1/2蛋白水平表达变化。结果 胰岛素可促进LNCaP细胞胰岛素受体的表达，抑制其增殖、活力、迁移及侵袭能力，同时抑制其Ras的表达及ERK1/2、MEK1/2的磷酸化（P<0.05）。结论 胰岛素可通过胰岛素受体抑制Ras-MEK-ERK信号通路的活化，从而抑制LNCaP细胞的增殖、活力、迁移及侵袭。

关键词: 胰岛素受体, MAPK信号通路, 胰岛素, 前列腺肿瘤

Abstract: Objective To study the inhibitory effect of insulin on LNCaP human prostate cancer cell line and its possible mechanism. Methods After LNCaP cells were treated with insulin, the expression of insulin receptor was detected with Real-time PCR, immunocytochemistry and Western blotting. The effects of insulin on cell growth, viability, migration and invasion were measured by cell counting, MTT, wound healing and Transwell. The activation of MAPK pathway was determined by Western blotting. Results Insulin increased the mRNA and protein expressions of INSR in LNCaP cells, and inhibited the cell growth, viability, migration and invasion. Expressions of key proteins in the MAPK pathway, including Ras, p-MEK and p-ERK, were significantly lowered by insulin. Conclusion Insulin can inhibit prostate cancer LNCaP cell line through MAPK signal pathway.

Key words: Insulin receptor, Prostatic neoplasms, MAPK pathway, Insulin

中图分类号: 

  • R737.25
[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics CA cancer[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2] 唐志柳, 白洁, 顾丽娜, 等. 2000～2010年我国前列腺癌和乳腺癌流行状况的系统性综述[J]. 中国肿瘤, 2013, 22(4):260-265.
[3] Saman D M, Lemieux A M, Nawal Lutfiyya M, et al. A review of the current epidemiology and treatment options for prostate cancer[J]. Dis Mon, 2014, 60(4):150-154.
[4] Lawrenson R, Obertová Z, Brown C, et al. The use of androgen deprivation therapy and chemotherapeutic agents in New Zealand men with prostate cancer[J]. J Cancer, 2014, 5(3):214-220.
[5] Kasper J S, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2056-2062.
[6] Rodriguez C, Patel A V, Mondul A M, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men[J]. Am J Epidemiol, 2005, 161(2): 147-152.
[7] Stagi S, Lapi E, Pantaleo M, et al. Type II diabetes and impaired glucose tolerance due to severe hyperinsulinism in patients with 1p36 deletion syndrome and a Prader-Willi-like phenotype[J]. BMC Med Genet, 2014, 15:16. doi:10.1186/1471-2350-15-16
[8] Leitzmann M F, Ahn J, Albanes D, et al. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial[J]. Cancer Causes Control, 2008, 19(10):1267-1276.
[9] Zelenko Z, Gallagher E J. Diabetes and Cancer[J]. Endocrinol Metab Clin North Am, 2014, 43(1):167-185.
[10] Starup-Linde J, Karlstad O, Eriksen S A, et al. CARING: the association of diabetes mellitus and cancer risk with focus on possible determinants—a systematic review and a meta-analysis[J]. Curr Drug Saf, 2013, 8(5):296-332.
[11] Wang Y, Zhu Y, Tian W, et al. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway[J]. Cancer Lett, 2012, 322(2):223-231.
[12] Sehiel R, Behschikow W, Steiner T, et al. Diabetes, insulin, and risk of cancer[J]. Methods Find Exp Clin Pharmacol, 2006, 28(3):169-175.
[13] Ametov A S. The contribution of current investigations to understanding the nature of type 2 diabetes mellitus, and treatment perspectives[J]. Ter Arkh, 2014, 86(1):4-9.
[14] 仲英洁, 胡云. 胰岛素抵抗和胰岛素受体亚型A与肿瘤[J]. 医学综述, 2012, 18(3): 339-341.
[15] J Sánchez-Gurmaches, L Cruz-Garcia, A Ibarz, et al. Insulin, IGF-I, and muscle MAPK pathway responses after sustained exercise and their contribution to growth and lipid metabolism regulation in gilthead sea bream[J]. Domest Anim Endocrinol, 2013, 45 (3):145-153.
[16] Neal C L, Mckeithen D, Odero-Marah V A. Snail negatively regulates cell adhesion to extracellular matrix and integrin expression via the MAPK pathway in prostate cancer cells[J]. Cell Adh Migr, 2011, 5(3):249-257.
[17] 高庆贞, 吕家驹, 张辉, 等. 阻断MAPK通路对前列腺癌细胞增殖的影响[J]. 山东大学学报:医学版, 2006, 44(5): 501-503.
[18] Bakin R E, Gioeli D, Sikes R A, et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells[J]. Cancer Res, 2003, 63(8):1981-1989.
[1] 张士宝 刘庆勇 阮喜云 陈杰 张建军 李宗武 杨广笑 王全颖. NT4-SAC-HA2-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[2] 张媛 李英敏 冯月秋 常彩云 潘华伟 王束玫. 血清脂联素水平与肥胖、胰岛素抵抗的关系探讨[J]. 山东大学学报(医学版), 2209, 47(6): 124-.
[3] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60-66.
[4] 董伟,邢乃栋,吕家驹,刘帅,孙亮,曹庆伟,董宇昊,刘钊,丁森泰. 靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 23-30.
[5] 邓轲,刘毅,盖中涛. 间充质干细胞对肠道病毒71型的易感性及miRNA的差异表达[J]. 山东大学学报（医学版）, 2017, 55(3): 25-31.
[6] 李健,徐冰,闫新峰,徐万菊,常晓天. 筛选TXNDC5与胰岛素相关信号通路关键基因的探讨[J]. 山东大学学报（医学版）, 2017, 55(3): 88-93.
[7] 李洪志,申永超,刘洁婷,赵孝金,初彦辉,袁晓环. 11β-HSD1抑制剂改善db/db小鼠胰岛素敏感性的实验研究[J]. 山东大学学报（医学版）, 2017, 55(10): 59-64.
[8] 贾月月,刘洪彬,李婧博,李敬,张江涛, 孙梅,石玉华. 多囊卵巢综合征患者颗粒细胞microRNA-200b的表达及影响[J]. 山东大学学报（医学版）, 2017, 55(1): 63-68.
[9] 李婧博,刘洪彬,贾月月,王泽,孙梅,石玉华. microRNA-183在PCOS胰岛素抵抗中的表达及其临床意义[J]. 山东大学学报（医学版）, 2017, 55(1): 69-74.
[10] 林栋,管庆波. 2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响[J]. 山东大学学报（医学版）, 2016, 54(7): 33-37.
[11] 夏传友,李路超,李孝峰,颜克强, 张念昭,范医东,刘承. 组蛋白甲基化酶SMYD3在前列腺癌组织的表达及对mTOR通路的影响[J]. 山东大学学报（医学版）, 2016, 54(5): 12-16.
[12] 张春霞,邹存华,宋冬冬,余江. P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J]. 山东大学学报（医学版）, 2016, 54(2): 68-74.
[13] 许艺博,季晓康,李向一,申振伟,薛付忠. 尿液pH与代谢综合征的相关性[J]. 山东大学学报（医学版）, 2016, 54(12): 82-85.
[14] 李笃民,王茜,李传福,王青. 合并Whipple三联征的多发性内分泌腺瘤1型——附2例报道[J]. 山东大学学报（医学版）, 2016, 54(1): 62-66.
[15] 韩博, 戚美, 谭薇薇, 杨木易. 去势抵抗性前列腺癌的发生发展机制及药物治疗新进展[J]. 山东大学学报（医学版）, 2015, 53(9): 1-7.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发